| Ab | Antibody |
| ADCC | Antibody-dependent cellular cytotoxicity |
| ADCP | Antibody-dependent cellular phagocytosis |
| ADCs | Antibody–drug conjugates |
| Ag | Antigen |
| APCs | Antigen-presenting cells |
| APRIL | A proliferation-inducing ligand |
| B7-H1 | B7-homologue 1 |
| BCL-2 | B-cell lymphoma-2 |
| BCMA | B-cell maturation antigen |
| BiTEs | Bispecific T cell engager mAbs |
| BM | Bone marrow |
| BMME | Bone marrow microenvironment |
| BMSCs | Bone marrow stromal cells |
| BMT | Bone marrow transplantation |
| Bregs | Regulatory B cells |
| CAR-T | Chimeric antigen receptor–T cell therapy |
| cDCs | Conventional dendritic cells |
| CCL | C-C motif ligand |
| CSF-1 | Colony-stimulating factor 1 |
| CTLA-4 | Cytotoxic T-lymphocyte antigen 4 |
| CTLs | Cytotoxic T lymphocytes |
| CXCL | C-X-C motif Chemokine ligand |
| CXCR | C-X-C motif Chemokine receptor |
| DAMPs | Damage-associated molecular patterns |
| Dara-VTD | Daratumumab plus bortezomib, thalidomide, and dexamethasone |
| DCs | Dendritic cells |
| ECM | Extracellular matrix |
| ECs | Endothelial cells |
| EMA | European Medicines Agency |
| EPCs | Endothelial progenitor cells |
| ERK | Extracellular signal-regulated kinase |
| FDA | Food and Drug Administration |
| FBs | Fibroblasts |
| Foxp3 | Forkhead box P3 |
| HLA | Human leukocyte antigen |
| IL | Interleukin |
| imDCs | Immature DCs |
| ImiDs | Immunomodulatory drugs |
| INF-γ | Interferon-γ |
| JAM-A | Junctional adhesion molecule A |
| mAb | Monoclonal antibodies |
| mDCs | Mature DCs |
| MDSCs | Myeloid-derived suppressor cells |
| MGUS | Monoclonal gammopathy of undetermined significance |
| MHC | Major histocompatibility complex |
| MM | Multiple myeloma |
| MSCs | Mesenchymal stromal cells |
| NK | Natural killer |
| OS | Overall survival |
| PCs | Plasma cells |
| PD-1 | Programmed death-1 |
| pDCs | Plasmacytoid dendritic cells |
| PD-L1 | PD ligand 1 |
| PFS | Progression-free survival |
| PGE2 | Prostaglandin E2 |
| PRRs | Pattern recognition receptors |
| RANKL | Receptor activator of nuclear factor kappa-B ligand |
| RR | Response rate |
| SMM | Smoldering multiple myeloma |
| TACI | Transmembrane activator CAML interactor |
| TAMs | Tumor-associated macrophages |
| TFH | T follicular helper |
| TGF-β | Transforming growth factor-β |
| Th | T helper |
| TIGIT | T cell immunoreceptor with immunoglobulin and ITIM domains |
| TLR | Toll-like receptor |
| TNF | Tumor necrosis factor |
| Tregs | Regulatory T cells |
| TTEs | Terminal effector CD8+ T cells |
| ULBPs | UL-binding proteins |
| VEGF | Vascular endothelial growth factor |